Whalesbook
Analyst Sentiment Shifts Following Q3 Financial Disclosures
Several Indian equities are experiencing renewed interest from brokerage firms, with a notable trend of rating upgrades and revised price targets emerging after the announcement of third-quarter fiscal year 2026 financial results. Dr Reddy's Laboratories, Rallis India, and Gujarat Gas have been the focal points of these adjustments, indicating varied performance drivers and growth prospects across different industry segments.
Dr Reddy's Laboratories: Emerging Markets Drive Performance
CLSA has moved its rating for Dr Reddy's Laboratories to 'Hold' and set a price target of ₹1,210. This action follows the company's Q3 FY26 performance, which saw revenue and profit figures exceed expectations. The company's expansion in emerging markets and India notably counterbalanced a contraction in its United States business, partly due to reduced Revlimid sales. CLSA projects that the US market, excluding Revlimid, will achieve single-digit growth, while other geographical regions are anticipated to achieve double-digit expansion. Furthermore, the drug semaglutide is identified as a prospective new revenue stream; it has secured Indian approval for a planned launch on March 21, 2026, with review submissions underway in Canada and filings anticipated across approximately 80 international markets. CLSA maintains a positive outlook on sustained growth from India and emerging markets for the company. As of January 22, 2026, Dr Reddy's Laboratories was trading at ₹6,050.50, with a market capitalization of approximately ₹1.55 lakh crore and a P/E ratio of 38.2x.
Rallis India: Business Transformation Yields Results
Hopwsbc has upgraded Rallis India to a 'Buy' recommendation, establishing a price objective of ₹300. This upgrade is based on the company's fiscal year 2026 third-quarter performance, which was better than anticipated. Adjusted profit after tax surpassed forecasts, with all business segments demonstrating resilience amid difficult market conditions. HSBC has observed that the company's business transformation initiatives are now demonstrating positive outcomes beyond its domestic crop protection segment, with indications of recovery noted in its seeds and exports operations. The brokerage's assessment also incorporates a significant 35% price reduction in the stock over the preceding six months, alongside enhanced clarity regarding future earnings. As of January 22, 2026, Rallis India was trading at ₹255.75, with a market capitalization of approximately ₹10,200 crore and a P/E ratio of 26.5x.
Gujarat Gas: Margin Strength Mitigates Volume Pressures
CLSA has maintained its 'Hold' rating on Gujarat Gas and increased its price target to ₹375. The company's standalone profit for the third quarter was aligned with projections, as improved unit margins compensated for a marginal shortfall in volumes. Unit EBITDA margins registered a notably positive performance, although overall volumes experienced a sequential decrease owing to a substantial reduction in industrial demand. Management has indicated that volumes in Morbi have rebounded following a price reduction in January, increasing from approximately 1.7 million standard cubic meters per day (mmscmd) in Q3 to around 2.2 mmscmd, with further increases projected to 3.0-3.2 mmscmd by February-March. The company has reaffirmed that its scheme of arrangement with GSPL and GSPC is progressing as scheduled for completion by early fiscal year 2027, subject to final regulatory approvals. CLSA has incorporated expectations for increased sales volumes in the fourth quarter, raising its earnings per share (EPS) estimate for FY26 by 10% and for FY27 and FY28 by 2% and 4%, respectively. As of January 22, 2026, Gujarat Gas was trading at ₹510.20, with a market capitalization of approximately ₹20,500 crore and a P/E ratio of 31.0x.
Sectoral Insights and Market Positioning
The adjustments reflect differing sector dynamics. The pharmaceutical sector, as seen with Dr Reddy's, is navigating global market shifts, with a focus on emerging markets and innovative drug pipelines. The agrochemical sector, represented by Rallis India, is showing resilience through business diversification and recovery signs in key segments. For Gujarat Gas, the city gas distribution sector continues to face challenges related to industrial demand but is supported by margin improvements and regional volume recoveries. The successful completion of corporate restructuring remains a key event to monitor for Gujarat Gas.